Stockscreener 앱 받기
4.06
3.79%
-0.16
시간 외 거래:
4.04
-0.02
-0.49%
Macrogenics Inc 주식(MGNX)의 최신 뉴스
MGNX Maintained by B. Riley Securities -- Price Target Raised to $11.00 - GuruFocus
B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating - marketscreener.com
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst? - Yahoo Finance
MacroGenics 2026: Revenue $32.83M, EPS $0.31— 10-Q Summary - TradingView
MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise - Stock Titan
Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A - Stock Titan
MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates - Investing.com Nigeria
MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS - MarketBeat
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
MacroGenics Q2 adj. EPS $(0.27) misses $(0.13) estimate; sales miss - scanx.trade
MacroGenics: Q2 Earnings Snapshot - Yahoo Finance
MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner - marketscreener.com
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position - The Manila Times
Gilead exercises option for MacroGenics pre-clinical bispecific program - The Pharma Letter
MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP - MarketBeat
Gilead exercises option on MacroGenics bispecific program By Investing.com - Investing.com UK
MacroGenics stock rises on $10M Gilead option exercise By Investing.com - Investing.com South Africa
MacroGenics stock rises on $10M Gilead option exercise - Investing.com
Gilead exercises option on MacroGenics bispecific program - Investing.com
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program - The Manila Times
MacroGenics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
MacroGenics (MGNX) Projected to Release Earnings on Thursday - MarketBeat
MGNX (NASDAQ: MGNX) holder files to sell 20,166 common shares under Rule 144 - stocktitan.net
Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX) - Stock Titan
MacroGenics Inc (MGNX) Institutional Confidence - TradingKey
BlackRock (MGNX holder) discloses 7.1% MacroGenics stake in Schedule 13G filing - Stock Titan
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha
Citizens reiterates MacroGenics stock rating ahead of ESMO data - Investing.com
Citizens reiterates MacroGenics stock rating ahead of ESMO data By Investing.com - Investing.com Canada
MacroGenics Inc (MGNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MacroGenics, Inc. Revenue Breakdown – NASDAQ:MGNX - TradingView
MGNX|MacroGenics Inc|Price:3.700|Chg%:-0.310 - TradingKey
MacroGenics Inc (MGNX) Cash Flow - TradingKey
MacroGenics, Inc. Revenue Breakdown – DUS:M55 - TradingView
TradingKey - TradingKey
MacroGenics slips on trial data for lead asset (MGNX:NASDAQ) - Seeking Alpha
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026 - The Manila Times
MacroGenics’ MGC026 meets Phase 1 trial milestone in SCCHN - Investing.com
MacroGenics (MGNX) Advances Phase 1 Study of MGC026 - GuruFocus
MacroGenics’ MGC026 meets trial threshold in head and neck cancer By Investing.com - Investing.com Nigeria
MacroGenics Advances MGC026 in Phase 1 Oncology Trial - TipRanks
MacroGenics’ MGC026 meets trial threshold in head and neck cancer - Investing.com
Entera Bio Leads Our Top 3 Penny Stocks To Consider - Sahm
MGNX stock holds focus as MacroGenics plans and pipeline metrics matter - Ad-hoc-news.de
MacroGenics (MGNX): Millennium group discloses 3.7% beneficial stake in amended 13G - Stock Titan
MacroGenics stock gains after FDA priority review as revenue rises and cash runway extends - Ad-hoc-news.de
MacroGenics Inc (NASDAQ: MGNX) Share Price, MGNX Stock News, MGNX Share Price & Updates - Kalkine
[144] MACROGENICS INC SEC Filing - Stock Titan
Form 144 MACROGENICS For: 13 July By Investing.com - Investing.com Nigeria
MacroGenics (MGNX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
MGNX Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Pipeline DevelopmentOperating Margin Analysis - dars.gov.et
MacroGenics, Inc. 8-K SEC Filing July 2026: Company Details, Stock Info, and Key Regulatory Disclosures - Minichart
MacroGenics (MGNX) Slides Further as Stock Hovers Near Key Support LevelsTime Weighted Price - DonanımHaber
MacroGenics announces upcoming board change with director resignation - TipRanks
Karen Ferrante to Resign from MacroGenics' Board Effective Sept 1, 2026 - TradingView
Board member Karen Ferrante to leave MacroGenics (MGNX) board in September 2026 - Stock Titan
Macrogenics, Inc. Announces Resignation of Karen Ferrante from Director Role, Effective September 1, 2026 - marketscreener.com
MacroGenics Inc highlights its oncology pipeline as investors track future catalysts - Ad-hoc-news.de
MacroGenics Sells GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million - Minichart
MacroGenics Completes Asset Sale, Shifts to R&D Focus - TipRanks
1.80%
1.77%
자본화:
|
볼륨(24시간):